The Impact of Off-Patent Drug Acquisitions on Prices

J Gen Intern Med. 2018 Jul;33(7):1007-1009. doi: 10.1007/s11606-018-4372-3.

Ravi Gupta¹, Alexis Henkel², Howard P Forman^{3

4

5}, Joseph S Ross^{6

7

8}

¹ Department of Medicine, Johns Hopkins Hospital and Johns Hopkins School of Medicine, Baltimore, MD, USA.
² Yale University, New Haven, CT, USA.
³ Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
⁴ Yale University School of Management, New Haven, CT, USA.
⁵ Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT, USA.
⁶ Department of Health Policy and Management, Yale University School of Public Health, New Haven, CT, USA. joseph.ross@yale.edu.
⁷ Section of General Internal Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA. joseph.ross@yale.edu.
⁸ Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA. joseph.ross@yale.edu.

No abstract available

Keywords: Acquisitions; FDA; Generics; Prescription drugs; Pricing.

Publication types